Icecure Medical Ltd Ord (ICCM) Stock Price, Quote & News

Company Profile

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Fax: 972 4 623 0222

Website: www.icecure-medical.com

Address:

7 Ha’Eshel St., PO Box 3163, Caesarea, Israel

Processresult Jun. 3 at 6:43 PM

$ICCM THEY DID THE 1 FOR 30 REVERSE SPLIT NOW SO THEY CAN FURTHER "DILUTE" THE STOCK... ( 5 ) YEAR "FDA" FIELD STUDY REQUIRED TO GET "ProSense" FULLY APPROVED, IF AT ALL THIS IS HEADING STRAIGHT INTO THE TOILET 🚽 🪠 TOMORROW MORNING

0 · Reply

WednesdayRanks Jun. 3 at 5:52 PM

$WXM $ICCM $SILO $WYHG touch

0 · Reply

WednesdayRanks Jun. 3 at 5:27 PM

$LYFT $CAMT $ICCM $LOBO grown

0 · Reply

Processresult Jun. 3 at 4:05 PM

$ICCM YOU WILL BE WAITING OVER ( 5 ) YEARS... IF "ProSense" EVEN EVER GETS FULLY APPROVED AT ALL... THIS IS A "LOSE YOUR ENTIRE ACCOUNT" COMPANY

0 · Reply

WednesdayRanks Jun. 3 at 3:27 PM

$WXM $ICCM waiting

0 · Reply

Processresult Jun. 3 at 3:00 PM

$ICCM ( 5 ) MORE YEARS... BEFORE THE ( FDA ) WOULD FULLY APPROVE "ProSense"

0 · Reply

Processresult Jun. 3 at 2:49 PM

$ICCM THERE IS "NO" 🚫 "FDA" "RESCUE"... THE "FDA" ALREADY TOLD THEM TO DO A ( 5 ) YEAR TRIAL... BEFORE THE "FDA" WILL FULLY "APPROVE" "ProSense" , IF AT ALL

0 · Reply

Kesiya Jun. 2 at 11:48 PM

$ICCM /B Buy now'

0 · Reply

thechad369 Jun. 2 at 9:27 PM

$ICCM you hate to see people get scammed with legitimate commercial phase micro caps, but here we are. I swore off micro caps that didnt have an approved product which brought me to this stock as my low $ speculative stock, ill be swearing these off as well 😂. This has an incredibly low short %, so i dont see it as a canidate for a short squeeze until a new short % float builds over the next 3-4 months. It would take unforeseen positive fundamental news before 2027 to think this gets back to $ 1 ($30 post)

0 · Reply

Zkoko_Bio Jun. 2 at 8:48 PM

$ICCM let's please be honest and call garbage, garbage.

0 · Reply

IceCure Medical implements 1-for-30 reverse share split for Nasdaq compliance

Jun 2, 2026, 8:30 AM EDT - 1 day ago

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

May 19, 2026, 8:30 AM EDT - 15 days ago

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

2026-05-14T14:38:22.000Z - 20 days ago

IceCure Medical price target lowered to $1 from $3 at Maxim

May 13, 2026, 4:30 PM EDT - 20 days ago

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

2026-05-12T15:06:32.000Z - 22 days ago

IceCure Medical reports Q1 EPS (6c) vs. (6c) last year

May 12, 2026, 11:00 AM EDT - 22 days ago

IceCure Medical Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 22 days ago

IceCure Medical Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 22 days ago

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

May 6, 2026, 8:30 AM EDT - 4 weeks ago

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

2026-05-04T11:09:48.000Z - 4 weeks ago

IceCure Medical initiated with a Buy at Alliance Global

Apr 21, 2026, 8:30 AM EDT - 6 weeks ago

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

2026-04-01T20:36:41.000Z - 2 months ago

IceCure Medical files to sell 16M ordinary share for holders

Apr 1, 2026, 8:00 AM EDT - 2 months ago

IceCure Medical Registration statement: Registration filing

2026-03-26T12:12:30.000Z - 2 months ago

IceCure Medical announces $4M registered direct offering

Mar 26, 2026, 8:00 AM EDT - 2 months ago

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

2026-03-25T12:36:52.000Z - 2 months ago

IceCure Medical reports results from clinical trial of ProSense for SRMs

Mar 25, 2026, 8:30 AM EDT - 2 months ago

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

2026-03-24T12:42:21.000Z - 2 months ago

IceCure Medical appoints Meir Peleg as CFO

Mar 24, 2026, 8:30 AM EDT - 2 months ago

IceCure Appoints Meir Peleg as Chief Financial Officer

Mar 20, 2026, 8:00 AM EDT - 2 months ago

IceCure Medical Registration statement: Registration filing

Mar 17, 2026, 11:00 AM EDT - 2 months ago

IceCure Medical Earnings Call Transcript: Q4 2025

Mar 17, 2026, 11:00 AM EDT - 2 months ago

IceCure Medical Earnings release: Q4 2025

Mar 17, 2026, 11:00 AM EDT - 2 months ago

IceCure Medical Annual report: Q4 2025

2026-03-17T12:49:34.000Z - 2 months ago

IceCure Medical reports FY25 EPS 24c vs 30c last year

Mar 17, 2026, 8:30 AM EDT - 2 months ago

IceCure Reports 2025 Full Year Financial & Operational Results

Mar 16, 2026, 8:00 AM EDT - 2 months ago

IceCure Medical Registration statement: Registration Filing

Mar 15, 2026, 7:00 AM EDT - 2 months ago

IceCure Medical Slides: Company presentation

2026-03-11T12:35:43.000Z - 3 months ago

IceCure Medical receives FDA approval for ProSense study

Mar 11, 2026, 8:30 AM EDT - 3 months ago

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

Mar 10, 2026, 8:30 AM EDT - 3 months ago

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

Mar 9, 2026, 8:30 AM EDT - 3 months ago

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

Mar 2, 2026, 8:30 AM EST - 3 months ago

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

2026-02-23T13:50:19.000Z - 3 months ago

IceCure Medical completes 5-year follow up study in kidney cancer cryoablation

Feb 23, 2026, 8:30 AM EST - 3 months ago

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Feb 19, 2026, 8:30 AM EST - 3 months ago

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

Feb 11, 2026, 8:30 AM EST - 4 months ago

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

2026-02-09T21:35:34.000Z - 4 months ago

IceCure Medical announces departure of CFO Ronen Tsimerman

Feb 9, 2026, 4:30 PM EST - 4 months ago

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Jan 28, 2026, 8:30 AM EST - 4 months ago

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

2026-01-12T13:51:33.000Z - 5 months ago

IceCure Medical sees FY25 ProSense sales $3.4M

Jan 12, 2026, 8:30 AM EST - 5 months ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

2025-12-17T13:35:34.000Z - 6 months ago

IceCure Medical expects significant increase in Q4 sales in North America

Dec 17, 2025, 8:30 AM EST - 6 months ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 10, 2025, 8:30 AM EST - 6 months ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

2025-12-05T13:40:46.000Z - 6 months ago

IceCure Medical receives Notice of Patent Allowance from CNIPA

Dec 5, 2025, 8:30 AM EST - 6 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Nov 19, 2025, 10:00 AM EST - 7 months ago

IceCure Medical Earnings Call Transcript: Q3 2025

Nov 19, 2025, 10:00 AM EST - 7 months ago

IceCure Medical Earnings release: Q3 2025

Nov 19, 2025, 8:54 AM EST - 7 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

2025-11-18T14:42:02.000Z - 7 months ago

IceCure Medical’s ProSense system receives regulatory approval in Switzerland

Nov 18, 2025, 8:30 AM EST - 7 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

2025-11-14T21:55:34.000Z - 7 months ago

IceCure Medical receives noncompliance notification from Nasdaq

Nov 14, 2025, 4:30 PM EST - 7 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 12, 2025, 8:30 AM EST - 7 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

2025-11-10T13:36:31.000Z - 7 months ago

IceCure Medical names Shay Levav as COO

Nov 10, 2025, 8:30 AM EST - 7 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 3, 2025, 8:30 AM EST - 7 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Oct 13, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 9, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

2025-10-07T10:10:18.000Z - 8 months ago

IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright

Oct 6, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical Transcript: Investor Update

Oct 6, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical Press release: Investor Update

2025-10-03T16:50:05.000Z - 8 months ago

Icecure Medical Ltd trading resumes

Oct 3, 2025, 12:28 PM EDT - 8 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:19 PM EDT - 8 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Sep 30, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 9 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 18, 2025, 8:30 AM EDT - 9 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 15, 2025, 8:30 AM EDT - 9 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 8, 2025, 8:30 AM EDT - 9 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 4, 2025, 8:30 AM EDT - 9 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:00 AM EDT - 9 months ago

IceCure Medical Registration statement: Registration Filing

Aug 13, 2025, 11:00 AM EDT - 10 months ago

IceCure Medical Earnings Call Transcript: Q2 2025

Aug 13, 2025, 11:00 AM EDT - 10 months ago

IceCure Medical Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 10 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Jul 29, 2025, 9:00 AM EDT - 11 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 25, 2025, 9:00 AM EDT - 11 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 24, 2025, 9:00 AM EDT - 11 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 10, 2025, 8:00 AM EDT - 11 months ago

IceCure Announces Commencement of Rights Offering

Jul 7, 2025, 8:00 AM EDT - 11 months ago

IceCure Medical Registration statement: Registration Filing

Jul 3, 2025, 8:30 AM EDT - 11 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:00 AM EDT - 11 months ago

IceCure Medical Registration statement: Registration Filing

Jun 25, 2025, 9:23 AM EDT - 1 year ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 8:00 AM EDT - 1 year ago

IceCure Medical Registration statement: Registration Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

IceCure Medical Registration statement: Registration Filing

Jun 9, 2025, 8:30 AM EDT - 1 year ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

May 28, 2025, 10:00 AM EDT - 1 year ago

IceCure Medical Earnings Call Transcript: Q1 2025

May 28, 2025, 10:00 AM EDT - 1 year ago

IceCure Medical Earnings release: Q1 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

IceCure Medical Reports First Quarter 2025 Financial Results

Processresult Jun. 3 at 6:43 PM

0 · Reply

WednesdayRanks Jun. 3 at 5:52 PM

$WXM $ICCM $SILO $WYHG touch

0 · Reply

WednesdayRanks Jun. 3 at 5:27 PM

$LYFT $CAMT $ICCM $LOBO grown

0 · Reply

Processresult Jun. 3 at 4:05 PM

$ICCM YOU WILL BE WAITING OVER ( 5 ) YEARS... IF "ProSense" EVEN EVER GETS FULLY APPROVED AT ALL... THIS IS A "LOSE YOUR ENTIRE ACCOUNT" COMPANY

0 · Reply

WednesdayRanks Jun. 3 at 3:27 PM

$WXM $ICCM waiting

0 · Reply

Processresult Jun. 3 at 3:00 PM

$ICCM ( 5 ) MORE YEARS... BEFORE THE ( FDA ) WOULD FULLY APPROVE "ProSense"

0 · Reply

Processresult Jun. 3 at 2:49 PM

$ICCM THERE IS "NO" 🚫 "FDA" "RESCUE"... THE "FDA" ALREADY TOLD THEM TO DO A ( 5 ) YEAR TRIAL... BEFORE THE "FDA" WILL FULLY "APPROVE" "ProSense" , IF AT ALL

0 · Reply

Kesiya Jun. 2 at 11:48 PM

$ICCM /B Buy now'

0 · Reply

thechad369 Jun. 2 at 9:27 PM

0 · Reply

Zkoko_Bio Jun. 2 at 8:48 PM

$ICCM let's please be honest and call garbage, garbage.

0 · Reply

Processresult Jun. 2 at 8:24 PM

$ICCM SOMEONE BOUGHT OVER ( 1.1 ) MILLION SHARES YESTERDAY AND TODAY...

0 · Reply

TwongStocks Jun. 2 at 8:03 PM

$ICCM Equity Corporate Actions Alert #2026 - 379 Information Regarding the Reverse Stock Split and CUSIP Number Change for IceCure Medical Ltd. (ICCM) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-379 IceCure Medical Ltd. (ICCM) will effect a one-for-thirty (1-30) reverse split of its Ordinary Shares. The reverse stock split will become effective on Thursday, June 4, 2026. In conjunction with the reverse split, the CUSIP number will change to M53071201.

0 · Reply

Processresult Jun. 2 at 6:53 PM

$ICCM SOMEONE BOUGHT OVER ( 1.1 ) MILLION SHARES YESTERDAY AND TODAY...

1 · Reply

DARKP00L Jun. 2 at 5:36 PM

$ICCM 08:43 on Jun. 02 2026 IceCure Medical Announces 1-For-30 Reverse Share Split, Effective June 4, 2026 #tradeideas

0 · Reply

justme_DC Jun. 2 at 5:02 PM

$ICCM Wow, doing early and at the max allowed by the vote :/ That is concerning as it gives the impression they want / need as much downside buffer as they can get.

0 · Reply

prismmarketview Jun. 2 at 4:20 PM

PRISM Mid-Day Movers: Cybersecurity and Aerospace & Defense are Today’s Leaders. Hub Cyber Security Ltd. (NASDAQ: $HUBC) is ripping again today, with the stock jumping about 65% to 0.8502 after a prior close of 0.515. Astrotech Corporation (NASDAQ: $ASTC) is in breakout mode today, with shares surging nearly 40% to 49.4444 from a previous close of 35.4. Other Notable Movers: Sleep Number Corp. ( $SNBR) up 20% Ascent Solar Technologies, Inc. ( $ASTI) up 18% IceCure Medical ( $ICCM) down -27% https://prismmarketview.com/prism-mid-day-movers-cybersecurity-and-aerospace-defense-are-todays-leaders-2/

0 · Reply